Robert R. Bies, PharmD

Robert R. Bies, PharmD is a contributing author on Psychiatrist.com. Robert R. Bies has authored or co-authored 3 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2014 and 2016. Their work focuses on Schizophrenia/Schizoaffective Disorders.

Schizophrenia/Schizoaffective Disorders

Frequent co-authors

Hiroyuki Uchida Takefumi Suzuki Gary Remington Hiroyoshi Takeuchi Masaru Mimura Bruce G. Pollock David Grönte Gagan Fervaha

Article

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial

October 26, 2016

When your patients with schizophrenia insufficiently respond to antipsychotic treatment, do you increase the dose? Do you check their plasma drug concentration? Read this CME article to find out...

Hiroyuki Uchida, Bruce G. Pollock, Shitij Kapur, et al

Original Research

Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study

July 22, 2014

Hiroyuki Uchida, Gary Remington, Koichiro Watanabe, et al

Original Research

Impact of Once- Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes: An Analysis of the CATIE Data

May 15, 2014

Hiroyuki Uchida, Gary Remington, Hiroyoshi Takeuchi, et al

Robert R. Bies, PharmD

Frequent co-authors

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial

Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study

Impact of Once- Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes: An Analysis of the CATIE Data

ELSEWHERE:

FOLLOW US:

Robert R. Bies, PharmD

Frequent co-authors

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial

Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study

Impact of Once- Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes: An Analysis of the CATIE Data

Live Webinar and Q&A With Dr Deligiannidis

Subscribe to readmore articles

Live Webinar
and Q&A With
Dr Deligiannidis

Subscribe to read
more articles